February 25, 2019
Daiichi Sankyo will revamp its R&D, supply chain, and medical affairs organizations effective April 1 as part of its efforts to place priority on its oncology franchise. The company’s R&D division will introduce a pharmacology and synthesis function-based organization, replacing...read more